- Report
- March 2018
- 174 Pages
Global
From €2425EUR$2,750USD£2,092GBP
- Report
- November 2023
- 250 Pages
Global
From €2161EUR$2,450USD£1,864GBP
- Report
- February 2023
- 143 Pages
North America
From €3043EUR$3,450USD£2,624GBP
- Report
- January 2024
- 250 Pages
Global
From €7011EUR$7,950USD£6,048GBP
- Drug Pipelines
- April 2021
- 78 Pages
Global
€19402EUR$22,000USD£16,735GBP
- Report
- October 2018
- 17 Pages
Global
From €8819EUR$10,000USD£7,607GBP
Uptravi (selexipag) is a medication used to treat pulmonary arterial hypertension (PAH). It is a prostacyclin receptor agonist, which works by relaxing the blood vessels in the lungs to improve blood flow. Uptravi is the first and only oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of PAH. It is also approved in the European Union and other countries.
The Uptravi market is a rapidly growing segment of the cardiovascular drugs market. It is estimated that the global PAH market will reach $4.5 billion by 2026, driven by the increasing prevalence of PAH and the introduction of new treatments. Uptravi is expected to be a major contributor to this growth.
Companies in the Uptravi market include Actelion Pharmaceuticals, United Therapeutics Corporation, GlaxoSmithKline, Bayer AG, and Pfizer Inc. Show Less Read more
